EP1592431A4 - Method of modulating il-6 - Google Patents
Method of modulating il-6Info
- Publication number
- EP1592431A4 EP1592431A4 EP04702261A EP04702261A EP1592431A4 EP 1592431 A4 EP1592431 A4 EP 1592431A4 EP 04702261 A EP04702261 A EP 04702261A EP 04702261 A EP04702261 A EP 04702261A EP 1592431 A4 EP1592431 A4 EP 1592431A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- modulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003900194 | 2003-01-15 | ||
AU2003900194A AU2003900194A0 (en) | 2003-01-15 | 2003-01-15 | Methods of modulating il-6 |
PCT/AU2004/000049 WO2004062675A1 (en) | 2003-01-15 | 2004-01-15 | Method of modulating il-6 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1592431A1 EP1592431A1 (en) | 2005-11-09 |
EP1592431A4 true EP1592431A4 (en) | 2007-08-22 |
Family
ID=30004901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04702261A Withdrawn EP1592431A4 (en) | 2003-01-15 | 2004-01-15 | Method of modulating il-6 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1592431A4 (en) |
AU (1) | AU2003900194A0 (en) |
CA (1) | CA2516398A1 (en) |
WO (1) | WO2004062675A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
GB0329667D0 (en) | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
GB0513881D0 (en) * | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
CN101108872B (en) * | 2006-07-21 | 2012-07-18 | 江苏中康药物科技有限公司 | Plants natural base extract and formulated product and use thereof |
WO2008064425A1 (en) * | 2006-11-30 | 2008-06-05 | Solbec Pharmaceuticals Limited | Glycoalkaloid and chemotherapeutic agent combinations and various uses thereof |
JP7355319B2 (en) * | 2017-11-24 | 2023-10-03 | 国立研究開発法人理化学研究所 | Anti-fatigue composition containing an IL-1β and/or IL-6 expression inhibitor for preventing and/or improving fatigue caused by intracerebral inflammation and its use |
CN112957364A (en) * | 2021-03-29 | 2021-06-15 | 杭州立效生物医药科技有限公司 | Medicine for treating renal tubular injury and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0020029A1 (en) * | 1979-05-02 | 1980-12-10 | Aruba (Qld.) Pty. Ltd. | Pharmaceutical compositions comprising steroid alkaloids |
US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
US20020006931A1 (en) * | 1998-04-09 | 2002-01-17 | Philip A. Beachy | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69131861T2 (en) * | 1990-01-18 | 2000-05-18 | Cura Nominees Pty Ltd | GLYCOAL CALALID |
AUPP968699A0 (en) * | 1999-04-09 | 1999-05-06 | Cura Nominees Pty Ltd | Therapeutic compositions and method for their preparation |
DE60207878T2 (en) * | 2001-09-28 | 2006-08-17 | Glycomed Sciences Ltd., Turramurra | SOLVENT EXTRACTION PROCESS |
AUPS329002A0 (en) * | 2002-07-01 | 2002-07-18 | Solbec Pharmaceuticals Limited | Glycoalkaloid compositions and various uses thereof |
-
2003
- 2003-01-15 AU AU2003900194A patent/AU2003900194A0/en not_active Abandoned
-
2004
- 2004-01-15 EP EP04702261A patent/EP1592431A4/en not_active Withdrawn
- 2004-01-15 WO PCT/AU2004/000049 patent/WO2004062675A1/en active Search and Examination
- 2004-01-15 CA CA002516398A patent/CA2516398A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0020029A1 (en) * | 1979-05-02 | 1980-12-10 | Aruba (Qld.) Pty. Ltd. | Pharmaceutical compositions comprising steroid alkaloids |
US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
US20020006931A1 (en) * | 1998-04-09 | 2002-01-17 | Philip A. Beachy | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
Non-Patent Citations (2)
Title |
---|
See also references of WO2004062675A1 * |
VILLUNGER A ET AL: "Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 8 FEB 1996, vol. 65, no. 4, 8 February 1996 (1996-02-08), pages 498 - 505, XP002421949, ISSN: 0020-7136 * |
Also Published As
Publication number | Publication date |
---|---|
CA2516398A1 (en) | 2004-07-29 |
WO2004062675A1 (en) | 2004-07-29 |
AU2003900194A0 (en) | 2003-01-30 |
EP1592431A1 (en) | 2005-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0325192D0 (en) | Method of use | |
GB0308731D0 (en) | Method of radiotherapy | |
ZA200403741B (en) | Method of timberland management | |
EP1597590A4 (en) | Method of scheduling | |
EP1577280A4 (en) | Method of deuterization | |
EP1675596A4 (en) | Method | |
EP1595850A4 (en) | Method of desalting | |
EP1592431A4 (en) | Method of modulating il-6 | |
GB0310634D0 (en) | Method of connecting components | |
GB0308893D0 (en) | Method of making emulsions | |
GB0306309D0 (en) | Method of treatment | |
EP1488046A4 (en) | Method of construction | |
GB0302572D0 (en) | Method of treatment | |
GB0322963D0 (en) | Methods of controlling reducant addition | |
SI1639831T1 (en) | Method for compression of data | |
EP1626053A4 (en) | Method of alpha-selective glycosylation | |
EP1676578A4 (en) | Method of stabilizing diarylvinylene compound | |
IL175170A0 (en) | Method of modulating hematopoiesis | |
AU2003299623A8 (en) | Method of making mercaptoalkylalkyldialkoxysilanes | |
GB0322897D0 (en) | Configuration method | |
EP1595129A4 (en) | Methods of identifying modulators of cellular glycosylation using gtrap3-18 | |
AU2003290512A1 (en) | Method of weldbonding | |
EP1612264A4 (en) | Organ-forming method | |
GB2408895B (en) | Method of network selection | |
GB0423692D0 (en) | Method of communicating |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050815 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/00 20060101ALI20070305BHEP Ipc: G01N 33/68 20060101ALI20070305BHEP Ipc: G01N 33/50 20060101AFI20070305BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070724 |
|
17Q | First examination report despatched |
Effective date: 20071109 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080520 |